Patents by Inventor Anders Robert Sorensen

Anders Robert Sorensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Single-chain insulin
    Patent number: 8883449
    Abstract: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: November 11, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Børglum Kjeldsen, Morten Schlein, Anders Robert Sørensen, Peter Madsen
  • Single-Chain Insulin
    Publication number: 20090170750
    Abstract: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.
    Type: Application
    Filed: October 15, 2008
    Publication date: July 2, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Thomas Borglum Kjeldsen, Asser Sloth Andersen, Morten Schlein, Anders Robert Sorensen, Peter Madsen
  • Use of 2,4-diaminothiazole derivatives
    Publication number: 20010039275
    Abstract: 2,4-Diaminothiazole derivatives which inhibit GSK-3 (glycogen synthase kinase-3) and which are useful for the treatment and/or prevention disorders and diseases wherein an inhibition of GSK-3 is beneficial, especially especially Alzheimer's disease, bipolar disorder, IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: January 31, 2001
    Publication date: November 8, 2001
    Inventors: Andrew Neil Bowler, Preben Houlberg Olesen, Anders Robert Sorensen, Bo Falck Hansen, Helle Worsaae, Peter Kurtzhals